Sirona Biochem Corp Stock Debt To Equity
| SBM Stock | CAD 0.07 0.01 13.33% |
Sirona Biochem Corp fundamentals help investors to digest information that contributes to Sirona Biochem's financial success or failures. It also enables traders to predict the movement of Sirona Stock. The fundamental analysis module provides a way to measure Sirona Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sirona Biochem stock.
Sirona | Debt To Equity |
Sirona Biochem Corp Company Debt To Equity Analysis
Sirona Biochem's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Sirona Biochem Debt To Equity | 470.90 % |
Most of Sirona Biochem's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sirona Biochem Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Sirona Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Sirona Biochem Corp has a Debt To Equity of 470%. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The debt to equity for all Canada stocks is notably lower than that of the firm.
Sirona Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sirona Biochem's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sirona Biochem could also be used in its relative valuation, which is a method of valuing Sirona Biochem by comparing valuation metrics of similar companies.Sirona Biochem is currently under evaluation in debt to equity category among its peers.
Sirona Fundamentals
| Return On Equity | -98.1 | ||||
| Return On Asset | -1.48 | ||||
| Operating Margin | (258.82) % | ||||
| Current Valuation | 20.11 M | ||||
| Shares Outstanding | 258.84 M | ||||
| Shares Owned By Insiders | 10.53 % | ||||
| Number Of Shares Shorted | 93.61 K | ||||
| Price To Book | 41.64 X | ||||
| Price To Sales | 456.22 X | ||||
| Revenue | 34.78 K | ||||
| Gross Profit | 621.75 K | ||||
| EBITDA | (2.26 M) | ||||
| Net Income | (2.54 M) | ||||
| Cash And Equivalents | 376.43 K | ||||
| Total Debt | 637.65 K | ||||
| Debt To Equity | 470.90 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (1.76 M) | ||||
| Short Ratio | 1.51 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.73 | ||||
| Beta | -0.02 | ||||
| Market Capitalization | 16.82 M | ||||
| Total Asset | 1.03 M | ||||
| Retained Earnings | (43.9 M) | ||||
| Working Capital | (843.55 K) | ||||
| Net Asset | 1.03 M |
About Sirona Biochem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sirona Biochem Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sirona Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sirona Biochem Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sirona Stock Analysis
When running Sirona Biochem's price analysis, check to measure Sirona Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sirona Biochem is operating at the current time. Most of Sirona Biochem's value examination focuses on studying past and present price action to predict the probability of Sirona Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sirona Biochem's price. Additionally, you may evaluate how the addition of Sirona Biochem to your portfolios can decrease your overall portfolio volatility.